Baseline factors such as post-menopausal status, ethnicity, and HER2+ tumor subtype were associated with a faster development of BMs, while treatments like adjuvant endocrine therapy and Palbociclib were found to delay BM onset. The gene discussed is ERBB2; the disease is neoplasm.